Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
Abstract Background Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune‐related adverse events (...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5085 |
| _version_ | 1797903114016129024 |
|---|---|
| author | Pengyuan Liu Mengna Ye Yajun Wu Lichao Wu Kaiping Lan Zhibing Wu |
| author_facet | Pengyuan Liu Mengna Ye Yajun Wu Lichao Wu Kaiping Lan Zhibing Wu |
| author_sort | Pengyuan Liu |
| collection | DOAJ |
| description | Abstract Background Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune‐related adverse events (irAEs), currently restrict their clinical application. Were these disadvantages to be overcome, more patients could derive prolonged benefits from ICIs. At present, many basic experiments and clinical studies using hyperthermia combined with ICI treatment (HIT) have been performed and shown the potential to address the above challenges. Therefore, this review extensively summarizes the knowledge and progress of HIT for analysis and discusses the effect and feasibility. Methods In this review, we explored the PubMed and clinicaltrials.gov databases, with regard to the searching terms “immune checkpoint inhibitor, immunotherapy, hyperthermia, ablation, photothermal therapy”. Results By reviewing the literature, we analyzed how hyperthermia influences tumor immunology and improves the efficacy of ICI. Hyperthermia can trigger a series of multifactorial molecular cascade reactions between tumors and immunization and can significantly induce cytological modifications within the tumor microenvironment (TME). The pharmacological potency of ICIs can be enhanced greatly through the immunomodulatory amelioration of immunosuppression, and the activation of immunostimulation. Emerging clinical trials outcome regarding HIT have verified and enriched the theoretical foundation of synergistic sensitization. Conclusion HIT research is now starting to transition from preclinical studies to clinical investigations. Several HIT sensitization mechanisms have been reflected and demonstrated as significant survival benefits for patients through pioneering clinical trials. Further studies into the theoretical basis and practical standards of HIT, combined with larger‐scale clinical studies involving more cancer types, will be necessary for the future |
| first_indexed | 2024-04-10T09:27:51Z |
| format | Article |
| id | doaj.art-9da3a62e7ac54b94ac1bcb7d4e4de54c |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T09:27:51Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-9da3a62e7ac54b94ac1bcb7d4e4de54c2023-02-19T18:54:07ZengWileyCancer Medicine2045-76342023-02-011233201322110.1002/cam4.5085Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomesPengyuan Liu0Mengna Ye1Yajun Wu2Lichao Wu3Kaiping Lan4Zhibing Wu5Oncology & Radiotherapy Department Zhejiang Hospital Hangzhou ChinaSecond Clinical Medical College Zhejiang Chinese Medical University Hangzhou ChinaDepartment of TCM Pharmacy Zhejiang Hospital Hangzhou ChinaCollege of Basic Medical Sciences Zhejiang Chinese Medical University Hangzhou ChinaOncology Department of Combination of Traditional Chinese and Western Medicine Tonglu Hospital of Traditional Chinese Medicine Hangzhou ChinaOncology & Radiotherapy Department Zhejiang Hospital Hangzhou ChinaAbstract Background Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune‐related adverse events (irAEs), currently restrict their clinical application. Were these disadvantages to be overcome, more patients could derive prolonged benefits from ICIs. At present, many basic experiments and clinical studies using hyperthermia combined with ICI treatment (HIT) have been performed and shown the potential to address the above challenges. Therefore, this review extensively summarizes the knowledge and progress of HIT for analysis and discusses the effect and feasibility. Methods In this review, we explored the PubMed and clinicaltrials.gov databases, with regard to the searching terms “immune checkpoint inhibitor, immunotherapy, hyperthermia, ablation, photothermal therapy”. Results By reviewing the literature, we analyzed how hyperthermia influences tumor immunology and improves the efficacy of ICI. Hyperthermia can trigger a series of multifactorial molecular cascade reactions between tumors and immunization and can significantly induce cytological modifications within the tumor microenvironment (TME). The pharmacological potency of ICIs can be enhanced greatly through the immunomodulatory amelioration of immunosuppression, and the activation of immunostimulation. Emerging clinical trials outcome regarding HIT have verified and enriched the theoretical foundation of synergistic sensitization. Conclusion HIT research is now starting to transition from preclinical studies to clinical investigations. Several HIT sensitization mechanisms have been reflected and demonstrated as significant survival benefits for patients through pioneering clinical trials. Further studies into the theoretical basis and practical standards of HIT, combined with larger‐scale clinical studies involving more cancer types, will be necessary for the futurehttps://doi.org/10.1002/cam4.5085hyperthermiaimmune checkpoint inhibitorsynergistic sensitizationtumor immunosuppression |
| spellingShingle | Pengyuan Liu Mengna Ye Yajun Wu Lichao Wu Kaiping Lan Zhibing Wu Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes Cancer Medicine hyperthermia immune checkpoint inhibitor synergistic sensitization tumor immunosuppression |
| title | Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes |
| title_full | Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes |
| title_fullStr | Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes |
| title_full_unstemmed | Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes |
| title_short | Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes |
| title_sort | hyperthermia combined with immune checkpoint inhibitor therapy synergistic sensitization and clinical outcomes |
| topic | hyperthermia immune checkpoint inhibitor synergistic sensitization tumor immunosuppression |
| url | https://doi.org/10.1002/cam4.5085 |
| work_keys_str_mv | AT pengyuanliu hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes AT mengnaye hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes AT yajunwu hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes AT lichaowu hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes AT kaipinglan hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes AT zhibingwu hyperthermiacombinedwithimmunecheckpointinhibitortherapysynergisticsensitizationandclinicaloutcomes |